(0.07%) 5 135.25 points
(0.06%) 38 464 points
(0.12%) 17 868 points
(-0.30%) $83.60
(1.77%) $1.957
(0.33%) $2 355.00
(0.54%) $27.68
(1.57%) $936.55
(-0.15%) $0.933
(-0.34%) $10.99
(-0.29%) $0.798
(1.23%) $93.00
@ $11.35
发出时间: 14 Feb 2024 @ 22:30
回报率: -2.56%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 3.37 %
Live Chart Being Loaded With Signals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...
Stats | |
---|---|
今日成交量 | 474 113 |
平均成交量 | 829 708 |
市值 | 784.82M |
EPS | $0 ( 2024-03-06 ) |
下一个收益日期 | ( $-0.850 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.47 |
ATR14 | $0.0110 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Vultaggio Vincent | Sell | 0 | Common Stock |
2024-04-05 | Vultaggio Vincent | Sell | 12 500 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 6 875 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 2 750 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
85.13 |
Last 97 transactions |
Buy: 9 826 125 | Sell: 711 798 |
音量 相关性
Zentalis Pharmaceuticals 相关性
10 最正相关 |
---|
10 最负相关 | |
---|---|
RAVN | -0.813 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Zentalis Pharmaceuticals 相关性 - 货币/商品
Zentalis Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2023 |
营收: | $0 |
毛利润: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.43M (0.00 %) |
EPS: | $-4.18 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-5.65 |
Financial Reports:
No articles found.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。